

# 1 **KinAce: a web portal for exploring kinase-substrate** 2 **interactions**

3 John A. P. Sekar<sup>1</sup>, Yan Chak Li<sup>1</sup>, Avner Schlessinger<sup>2,3,\*\*</sup>, Gaurav Pandey<sup>1,4,\*</sup>

4 <sup>1</sup>Department of Genetics and Genomic Sciences, Icahn Genomics Institute, Icahn School  
5 of Medicine at Mount Sinai, New York, NY 10029, USA.

6 <sup>2</sup>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New  
7 York, NY 10029, USA.

8 <sup>3</sup>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at  
9 Mount Sinai, New York, New York 10029, USA.

10 <sup>4</sup>Lead Contact

11 \*\*Correspondence: [avner.schlessinger@mssm.edu](mailto:avner.schlessinger@mssm.edu)

12 \*Correspondence: [gaurav.pandey@mssm.edu](mailto:gaurav.pandey@mssm.edu)

## 13 **Abstract**

14 Interactions between protein kinases and their substrates are critical for the modulation  
15 of complex signaling pathways. Currently, there is a large amount of information available  
16 about kinases and their substrates in disparate public databases. However, these data are  
17 difficult to interpret in the context of cellular systems, which can be facilitated by examining  
18 interactions among multiple proteins at once, such as the network of interactions that  
19 constitute a signaling pathway. We present KinAce, a user-friendly web portal that  
20 integrates and shares information about kinase-substrate interactions from multiple  
21 databases of post-translational modifications. KinAce enables the visual exploration of  
22 these interactions in systems contexts, such as pathways, domain families, and custom  
23 protein set inputs, in an interactive fashion. We expect KinAce to be useful as a knowledge  
24 discovery tool for kinase-substrate interactions, and the aggregated KinAce dataset to be  
25 useful for protein kinase studies and systems-level analyses. The portal is available at  
26 <https://kinace.kinametrix.com/>.

## 27 **Keywords**

28 network visualization, knowledge discovery, data sharing, post-translational modification  
29 databases, cell signaling, systems biology

## 30 Introduction

31 Kinase proteins and their substrates are critical to cell signaling<sup>1-4</sup>. Dysregulation of  
32 kinases is involved in multiple pathologies, such as cancer, neurodegeneration,  
33 cardiovascular disease and infectious diseases, making kinases and their substrates  
34 priority targets for drug development<sup>5-7</sup>. Kinase-substrate interactions are known to be  
35 complex, where, for example, a particular kinase can phosphorylate multiple substrates,  
36 or a particular substrate can be phosphorylated by multiple kinases at one or more  
37 site(s)<sup>4,8,9</sup>. Understanding kinase function requires examining these interactions at multiple  
38 scales, from their structural aspects<sup>10-13</sup>, to their participation in specific pathways<sup>14-18</sup>, to  
39 the systems-level effects that they produce<sup>3,4,9,19</sup>.

40 Currently, there is a wealth of information available about kinase-substrate interactions  
41 disseminated by a number of public tools and web portals. Some focus on molecular  
42 features of kinases, such as their structural conformations (e.g., KinaMetrix<sup>10</sup> and  
43 KinCore<sup>11</sup>) and druggability (e.g., KLIFS<sup>12</sup>). Others focus on molecular features of  
44 substrates targeted by kinases, specifically phosphorylation sites (e.g., PhosphoSitePlus<sup>20</sup>,  
45 iPTMNet<sup>21</sup> and EPSD<sup>22</sup>) and motifs (e.g., The Kinase Library<sup>13</sup>). There are also portals that  
46 focus on phylogenetic classification of kinases (e.g., KinHub<sup>23</sup> and Coral<sup>24</sup>) and information  
47 about understudied kinases (e.g., The Dark Kinome Knowledgebase<sup>25</sup>). Additionally,  
48 extensive information about kinase interactions is presented in protein databases like  
49 UniProt<sup>26</sup> and BioGRID<sup>27</sup>. However, only a relatively small fraction of the available data on  
50 these interactions is interpretable in a functional context. For example, the vast majority  
51 of experimentally known phosphorylation sites have no associated kinase(s)<sup>20,21</sup>. Of the  
52 known kinase-substrate interactions, only a few well-understood ones have been  
53 incorporated into curated pathway databases (e.g., KEGG<sup>28</sup>, Reactome<sup>29</sup> and  
54 PathwayCommons<sup>30</sup>). Thus, there is an opportunity to uncover new kinase functionality by  
55 examining the aggregated molecular-level data on these interactions from a systems  
56 perspective. Visualizing and analyzing kinase-substrate interactions in the context of  
57 functional groupings like pathways can yield useful knowledge about kinase biology that  
58 can be leveraged for applications like drug discovery.

59 To address this important need, we have developed the KinAce web portal for  
60 aggregating, sharing and visualizing kinase-substrate interactions in the human genome.  
61 KinAce aggregates and shares a comprehensive dataset of kinase-substrate interactions  
62 from PhosphoSitePlus<sup>20</sup>, iPTMNet<sup>21</sup> and EPSD<sup>22</sup>, which are three large databases of post-  
63 translational modifications with recent and regular updates, and, which also provide  
64 coverage of several other data sources. KinAce provides multiple ways to visualize these  
65 interactions in varied functional/systems contexts, such as pathways, domain families and  
66 custom sets of genes provided by the user (e.g., from gene expression studies).  
67 Collectively, the data and visualization capabilities provided by KinAce represent a unique  
68 resource for exploring kinase-substrate interactions that complement the current  
69 ecosystem of tools for analyzing kinase data.

## 70 **Materials and Methods**

### 71 **Aggregating kinase-substrate interaction data**

72 The set of known human kinase-substrate interactions is continuously evolving. As a  
73 consequence, there are a large number of kinase-substrate interaction databases that  
74 overlap with each other significantly<sup>31</sup>. They are also maintained to different extents, and  
75 are standardized, e.g., in the proteins names they use, to different extents.

76 To build a comprehensive dataset of kinase-substrate interactions, we selected resources  
77 capturing the largest amount of public information, and with the most recent and regular  
78 updates. Additionally, it was important that the resources we selected contain references  
79 for each interaction, typically to the original publication, for data provenance. Three  
80 resources fit our criteria:

- 81 1. PhosphoSitePlus<sup>20</sup>, the largest continuously maintained database of expert-curated  
82 kinase-substrate interactions;
- 83 2. iPTMNet<sup>21</sup>, a database that curates information from PhosphoSitePlus and  
84 PhosphoELM<sup>32</sup>, as well as information extracted by text-mining of scientific literature;
- 85 3. EPSD<sup>22</sup>, an annotated collection of multiple curated databases, including  
86 PhosphoELM, PSEA<sup>33</sup>, PostMOD<sup>34</sup>, and RegPhos<sup>35</sup>, as well as a subset of  
87 PhosphoSitePlus.

88 We aggregated kinase-substrate interactions from the most current versions of the  
89 respective databases as of October 4<sup>th</sup>, 2023 (PhosphoSitePlus v6.7.1.1, iPTMNet v5.0,  
90 EPSD v1.0). To standardize protein and gene names, we cross-referenced them with  
91 protein identifiers from the reviewed subset of the UniProt human proteome<sup>26</sup> and gene  
92 symbols from HGNC<sup>36</sup> current on the same date. Additionally, we incorporated kinase-  
93 specific data from KinHub<sup>23</sup>, Coral<sup>24</sup> and the Dark Kinome Knowledgebase<sup>25</sup>, such as  
94 memberships of kinase proteins in phylogenetic groups<sup>37</sup>.

95 Each entry in the aggregated KinAce dataset is a triplet involving a kinase, a substrate and  
96 the site on the latter phosphorylated by the kinase. From these, we extracted unique  
97 kinase-substrate pairs, which in turn constitute the kinase-substrate interaction network  
98 used for visualizations on KinAce. The full interaction dataset, along with associated  
99 information like the source database(s), can be downloaded from the portal directly.

## 100 **The KinAce portal and interface**

101 KinAce is a web-based portal for sharing and visualizing the network of human kinase-  
102 substrate interactions (Figure 1). The portal is available at <https://kinace.kinamatrix.com/>.

103 One of the main features of KinAce is the ability to visualize known kinase-substrate  
104 interactions within selected sets of proteins as a network diagram. KinAce provides  
105 multiple ways to select these sets of proteins (Figure 1a), organized into four main tabs on  
106 the portal:

- 107 1. select a single protein on the Proteins tab,
- 108 2. select one of several curated pathway from KEGG<sup>28</sup> on the Pathways tab,
- 109 3. select one of several InterPro<sup>38</sup> domains on the Domains tab, and
- 110 4. provide a set of proteins on the Custom protein sets tab.


111 The network diagram produced (Figure 1b) displays kinase and non-kinase proteins in the  
112 selected set as colored and gray nodes respectively. Kinase nodes are colored by their  
113 phylogenetic group membership<sup>23,24,37</sup>. Interactions from kinases to their respective  
114 substrates are represented as directed edges. The user can move nodes around, as well  
115 as zoom in or out, to find the most meaningful layout for the displayed network. The left  
116 sidebar (Figure 1c) includes additional layout choices, as well as the option to unhide  
117 proteins with no interaction data. The user can also expand the network to include  
118 additional proteins adjacent to those in the selected set. Finally, the visualized network can  
119 be downloaded as an image (PNG), table of interactions (CSV) or in commonly used graph  
120 formats (GML<sup>39</sup>, GraphML<sup>40</sup> and DOT<sup>41</sup>).

121 Notably, data can be traced back to their original source(s). When the user clicks on an  
122 edge in a network diagram, the panel on the right (Figure 1c) displays information about  
123 the corresponding interaction, including

- 124 • the name of the kinase, and a link to its UniProt page,
- 125 • the name of the substrate, and a link to its UniProt page,
- 126 • a list of the known sites on the substrate phosphorylated by the kinase, and,
- 127 • links to the original database source(s) from which the interaction was obtained.

128 The user can follow these links to retrieve the primary literature reference(s) supporting  
129 each interaction. In fact, we used the KinAce web portal to retrieve all supporting  
130 references for specific kinase-substrate interactions mentioned in this paper.

131 **Figure 1: KinAce functionalities.** The KinAce web portal aggregates, shares and visualizes  
132 kinase-substrate interactions in the human genome from established databases of post-  
133 translational modifications. **(a) Choosing sets of proteins.** The tabs highlighted provide different  
134 ways to select sets of proteins for which kinase-substrate interactions will be displayed: individual  
135 proteins and their interactors, curated pathways from KEGG, protein families mapped to InterPro  
136 domains, and custom protein sets provided by the user. **(b) Visualizing kinase-substrate**  
137 **interactions.** Interactions within the selected set are shown as a network of directed edges from  
138 kinase nodes to substrate nodes. Kinase nodes are colored by kinase group and non-kinase nodes  
139 are colored gray. **(c) Interacting with the visualization.** The left sidebar shows the legend for  
140 node colors, an option for including proteins that are one degree away from the selected set, an  
141 option for unhiding nodes without edges, layout and export options. **(d) Provenance of data.**  
142 When the user selects an edge in the displayed network, the right panel displays information about  
143 the corresponding interaction, including links to the database sources from which the interaction  
144 was obtained. The user can follow these links to retrieve the literature reference(s) that reported  
145 that interaction. The specific example shown in this figure is the p53 signaling pathway visualized  
146 in the Pathway tab with the CDK4-TP53 interaction selected.




## 148 Results and Discussion

### 149 The KinAce dataset

150 The data aggregated from the most recent versions of PhosphoSite, iPTMNet and EPSD  
151 consisted of 16,360 unique kinase-substrate-site triples, representing 8,365 unique  
152 kinase-substrate pairs involving 416 kinases and 2,707 non-kinases. When we analyzed  
153 the original data source of each pair, we found that the three databases overlapped  
154 substantially, but also contributed several unique interactions individually (Figure 2a). The  
155 majority of interactions in the resulting dataset were between kinases and non-kinases,  
156 but there were also a notable number of autophosphorylations (n=229) and interactions  
157 between non-unique pairs of kinases (n=1,016) (Figure 2b). A small number of kinases  
158 and substrates dominated a large number of interactions (Figure S1). The full dataset can  
159 be downloaded directly from the portal.

160 **Figure 2: Kinase-substrate interaction statistics in the KinAce dataset.** KinAce aggregated a  
161 dataset of 8,365 kinase-substrate interactions from the PhosphoSitePlus, EPSD and iPTMNet  
162 databases. **(a) Breakdown of interactions by data sources.** The three sources overlapped, but  
163 also contributed unique interactions to the KinAce dataset. **(b) Breakdown of data by interaction**  
164 **types.** The majority of the interactions include interactions between kinases and non-kinases  
165 (n=7,124), but a substantial number of interactions either involved two different kinases (n=1,016),  
166 or were autophosphorylations (n=229).





169

## 170 **Exploring interactions of individual proteins with KinAce**


171 KinAce can be used to identify kinase-substrate interactions among sets of proteins of  
172 interest to the user.

173 The Proteins tab displays the known interactions of a protein selected by the user, which  
174 may be a kinase or a non-kinase. The network produced is a system-wide summary of  
175 kinase regulation involving the protein. For example, consider the visualization centered  
176 on BRAF, a well-known oncoprotein and component of the MAPK signaling pathway<sup>42</sup>  
177 (Figure 3a). Outgoing edges from BRAF highlight substrates of BRAF, which not only  
178 include the canonical MAP2K1 and MAP2K2 kinases, but also non-kinases with diverse  
179 functions, such as the apoptosis promoter BAD<sup>43</sup>, the translation elongation factors EEF1A  
180 and EEF1A2<sup>44</sup>, and the ion transporter SLC9A1<sup>45</sup>. Incoming edges to BRAF indicate  
181 kinases that regulate BRAF, such as AKT1<sup>46</sup> and AKT3<sup>47</sup>, as well as feedback from  
182 downstream proteins like MAPK1 and MAPK3<sup>48</sup>. This visualization is also effective for non-  
183 kinases. For example, the network centered on SLC9A1 (Figure 3b) displays the diverse  
184 range of kinases it interacts with in addition to BRAF, such as RPS6KA1 and ROCK  
185 kinases<sup>49</sup>, as well as AKT1<sup>50</sup> and MAPK1<sup>51</sup>. Finally, the visualization permits traversing the  
186 network: double-clicking on a node recenters the visualization on the corresponding  
187 protein.

188 The Custom protein sets tab visualizes the kinase-substrate interactions among a set of  
189 proteins provided by the user. This allows the user to generate networks for any functional  
190 context of interest. For example, a user interested in the overlap between insulin receptor  
191 (INSR) and EGFR pathways<sup>52</sup> can display the interactions involving the receptors EGFR  
192 and INSR and a select set of downstream proteins like the kinase MAPK1, the scaffold  
193 protein GAB1, insulin substrate IRS1 and the phosphatase PTPN1 (Figure 3c).

194 To explore additional interactions relevant to the proteins of interest, the user can select  
195 the option in the sidebar to include kinases and substrates that interact with the proteins  
196 shown in a network. For example, when we enable this option for the custom set of BRAF  
197 and RAF1, the network produced includes several new proteins (Figure 3d). Notably, it  
198 enables a systems-level comparison of BRAF and RAF1: we can delineate interactions  
199 common to BRAF and RAF1 on the diagram (e.g., MAP2K1) versus interactions unique to  
200 them (e.g., AKT3 and SRC). This approach is useful for non-kinases also. For example, we  
201 can see that the dataset includes more interactions with kinases for EEF1A1 than for  
202 EEF1A2 (Figure 3e).

203 **Figure 3: Exploring kinase-substrate interactions of proteins using KinAce.** The Proteins tab  
204 displays all interactions of a selected protein. **(a) Interactions of the kinase BRAF.** Outgoing  
205 edges point to proteins phosphorylated by BRAF, such as MAP2Ks and non-kinases EEF1As and  
206 SLC9A1. Incoming edges indicate kinases that phosphorylate BRAF such as AKTs as well as  
207 downstream MAPKs. **(b) Interactions of the non-kinase SLC9A1.** Incoming edges indicate  
208 interactions with multiple kinases such as BRAF, AKT1 and ROCK1. The Custom protein sets tab  
209 lets the user specify any set of proteins within which to visualize interactions. The user can expand  
210 the network by selecting the option to include proteins adjacent to the selected set. **(c) EGFR-**  
211 **INSR crosstalk.** A custom set of proteins focused on overlap between EGFR and INSR pathways.  
212 **(d) Comparing RAF kinases.** The expanded network for the custom set of BRAF and RAF1 can  
213 be used to elucidate their shared versus exclusive interactions. **(e) Comparing EEF1A proteins.**  
214 The expanded network for the custom set of EEF1A1 and EEF1A2 shows the differences in the  
215 interactions they have with various kinases.





## 217 **Exploring pathways with KinAce**

218 KinAce can be used to examine kinase-substrate interactions among proteins in specific  
219 pathways of interest, as well as make inferences.

220 Specifically, the Pathways tab enables visualizing and analyzing kinase-substrate  
221 interactions in several curated pathways from the KEGG database<sup>28</sup>. For example, when  
222 examining the network produced for the p53 signaling pathway (Figure 1), one can identify  
223 various kinases involved in checkpoint signaling<sup>53</sup> such as checkpoint kinases (CHEK1  
224 and CHEK2), DNA damage sensors (ATM and ATR), multiple cyclin-dependent kinases  
225 (CDKs) and others. Additionally, one can identify several important non-kinases including  
226 tumor suppressors TP53 and TP73, the oncogene MDM2, caspases (CASP8, CASP9),  
227 cyclins (CCNB1, CCNE1), among others. This view of the pathway is complementary to  
228 other visualizations<sup>28-30</sup> used by the community, as it focuses on kinase-substrate  
229 interactions.

230 The grid layout option can be effective for exploring pathways with large protein sets, such  
231 as MAPK signaling (Figure S2). However, for several pathways, the defined protein sets  
232 include many kinase substrates but not kinases. In these cases, the sidebar option to  
233 include adjacent proteins can be useful for discovering regulatory interactions. For  
234 example, expanding the currently disconnected KinAce network of the folate biosynthesis  
235 pathway (Figure 4a) revealed kinases that target metabolic enzymes in the pathway  
236 (Figure 4b), such as CAMK2 kinases targeting SPR<sup>54</sup>, an enzyme involved in several  
237 disease pathologies<sup>55</sup>.

238 Finally, to assess the general usefulness of the KinAce data for understanding pathways,  
239 we examined the enrichment of KEGG pathways in the kinase substrates included in the  
240 dataset using the Enrichr platform<sup>56,57</sup>. This analysis highlighted 201 significantly enriched  
241 pathways in 6 KEGG categories (Figure S3a), including environmental information  
242 processing (receptor- and small-molecule-activated pathways), genetic information  
243 processing (transcription, replication, DNA repair etc.), metabolism, cell-scale phenomena  
244 (cell cycle, autophagy, motility etc.), organism-level systems (endocrine, digestive,  
245 circulatory etc.), and a range of human pathologies, such as cancer, infectious disease,  
246 cardiovascular disease and neurodegeneration. The full set of enriched pathways and the  
247 corresponding p-values are reported in Appendix 1.

248 The above examples and results demonstrate the utility of KinAce and its underlying data  
249 for systems biology, specifically pathway analyses.

## 250 **Exploring domain groups with KinAce**


251 KinAce can be also used to examine domain composition of kinases and substrates from  
252 a systems perspective.

253 Specifically, the Domains tab enables selecting sets of kinases and substrates that share  
254 InterPro domains<sup>38</sup>, and potentially highlight shared patterns of regulation. For example,  
255 the network for the SH3 domain (Figure S4) highlights its close association with Src-type  
256 kinases like SRC, FYN, FGR, LCK, LYN etc<sup>58</sup>. Additionally, InterPro domains can serve as  
257 an entry point for examining kinase regulation in a functional context. For example,  
258 phosphorylation of histone deacetylases (HDACs) is essential to normal physiological  
259 function<sup>59</sup>, and in recent years, was found to be disrupted by pathogens like SARS-CoV2<sup>60</sup>.  
260 Selecting the option to include adjacent proteins expands the currently disconnected  
261 KinAce network of the histone deacetylase domain (Figure 4c) and enables a broader  
262 examination of kinases that phosphorylate HDACs (Figure 4d).

263 Finally, to assess the general utility of KinAce and its data for functional studies based on  
264 domain composition, we conducted an enrichment analysis of the kinase substrates  
265 included therein against InterPro domain annotations using Enrichr<sup>56,57</sup>. The analysis  
266 produced 147 significantly enriched InterPro terms. Although there is no universally  
267 accepted functional classification of domain terms, we identified five general functional  
268 categories among the enriched terms (Figure S3b): nuclear functions (e.g., DNA-binding,  
269 RNA recognition and other mechanisms involved in transcription, replication, chromatin  
270 remodeling, etc.), cytoplasmic proteins with primarily protein-binding function (e.g.,  
271 adaptors, scaffolds, small-molecule sensors, and ligand receptors), proteins with catalytic  
272 function (e.g., kinases, phosphatases, phosphodiesterases, lipid kinases, GTPases, and  
273 peptidases), structural proteins that are part of the cytoskeleton and extracellular matrix,  
274 and membrane proteins with transport function (e.g., ion channels and permeases). The  
275 full set of enriched domain terms and the corresponding p-values are reported in  
276 Appendix 2.

277 The above examples and results highlight the usefulness of the KinAce dataset for users  
278 interested in protein function represented by domain composition.

279 **Figure 4: Exploring kinase-substrate interactions in functional contexts, such as pathways**  
280 **and shared domains using KinAce.** The Pathways tab displays interactions from a selected  
281 pathway from KEGG database. The Domains tab displays interactions of proteins that share a  
282 selected domain. If the selected protein sets do not include kinases, expanding the network to  
283 include adjacent proteins can reveal regulatory interactions. **(a) The folate biosynthesis pathway.**  
284 This network, selected in the Pathways tab, shows a number of metabolic enzymes and no kinase-  
285 substrate interactions. **(b) The expanded view** reveals regulatory interactions such as  
286 phosphorylation of SPR by CAMK2 kinases. **(c) Proteins with the histone deacetylase domain.**  
287 This network, selected in the Domains tab contains multiple HDAC proteins and no kinases.  
288 The **expanded view** reveals the wide range of kinases that phosphorylate HDACs, as well as other  
289 interactions.



## 291 **Conclusion**

292 The KinAce web portal is a user-friendly resource for exploration and systems analysis of  
293 interactions between human protein kinases and their substrates. KinAce aggregates and  
294 shares kinase-substrate interactions from several established databases of post-  
295 translational modifications, and helps visualize this dataset as interactive networks.  
296 Specifically, the portal provides multiple ways to specify protein sets of interest for  
297 visualization, such as interactomes of individual proteins, proteins organized into  
298 pathways, proteins sharing domains, and user-defined custom protein sets. Individual  
299 interactions highlighted on these visualizations can be traced back to database sources  
300 and their corresponding literature references. The aggregated KinAce dataset is a useful  
301 resource for future kinase studies and systems-level analyses, as was demonstrated using  
302 functional enrichment analysis of these data with biological pathways and domains. The  
303 results from the dataset and the visualization features highlighted in this paper illustrate  
304 the utility of the KinAce resource for systems-level study and applications of kinases and  
305 their substrates.

## 306 **Acknowledgements**

307 We thank David Stein for assisting with web portal deployment, as well as Noah Herrington  
308 for proof-reading this manuscript and providing useful comments. This work was  
309 supported by NIH grant U01CA271318.

## 310 **Author Contributions**

311 Conceptualization, Data Curation, Writing – Original Draft, J.A.P.S.; Visualization, Software,  
312 J.A.P.S. and Y.C.L.; Writing – Review & Editing, J.A.P.S., A.S., and G.P.; Resources,  
313 Supervision, Project Administration, Funding Acquisition, A.S., and G.P.

## 314 **STAR Methods**

### 315 **Resource Availability**

#### 316 **Lead contact**

317 For more information, please contact Gaurav Pandey at [gaurav.pandey@mssm.edu](mailto:gaurav.pandey@mssm.edu).

#### 318 **Data and code availability**

319 The KinAce portal is available at <https://kinace.kinamatrix.com/>. The paper aggregates  
320 and analyzes publicly available data. The aggregated dataset and open-source code for  
321 the portal is maintained at <https://github.com/GauravPandeyLab/KinAce> and was also  
322 deposited at <https://zenodo.org/doi/10.5281/zenodo.10212985> on November 28, 2023.

## 323 **Method Detail**

### 324 **Web portal construction**

325 The KinAce portal was built as a Shiny<sup>61</sup> web app in the R ecosystem. The different tabs  
326 and their layouts were constructed using the *flexdashboard*<sup>62</sup> package. Network  
327 visualizations were constructed using the *visNetwork*<sup>63</sup> package and layouts are computed  
328 using the *igraph*<sup>64</sup> package.

329 The portal is deployed on Amazon Web services under the KinaMetrix domain  
330 (<https://kinace.kinametrix.com/>).

## 331 **Quantification and Statistical Analysis**

### 332 **Functional analyses of kinase substrates**

333 To examine kinase-modulated cellular functions represented in the KinAce dataset, we  
334 performed gene set enrichment on all substrates included against InterPro domains<sup>38</sup> and  
335 KEGG pathways<sup>28</sup>. Specifically, we used the GSEAPy<sup>65</sup> software to run these enrichment  
336 analyses on the Enrichr<sup>56</sup> platform against the InterPro\_Domains\_2019 and  
337 KEGG\_2021\_Human gene set libraries. We used the hypergeometric test at a significance  
338 level of 0.05 with correction for multiple hypotheses testing applied using the Benjamini-  
339 Hochberg procedure<sup>66</sup>.

340

## 341 Key Resources

RESOURCE	SOURCE	IDENTIFIER
<b>Kinase-substrate interaction data</b>		
PhosphoSitePlus	20	<a href="https://www.phosphosite.org/">https://www.phosphosite.org/</a>
iPTMNet	21	<a href="https://research.bioinformatics.udel.edu/iptmnet/">https://research.bioinformatics.udel.edu/iptmnet/</a>
EPSD	22	<a href="https://epsd.biocuckoo.cn/">https://epsd.biocuckoo.cn/</a>
<b>Kinases and group classification</b>		
KinHub	23	<a href="http://www.kinhub.org/">http://www.kinhub.org/</a>
Coral	24	<a href="https://phanstiel-lab.med.unc.edu/CORAL/">https://phanstiel-lab.med.unc.edu/CORAL/</a>
Dark Kinome Knowledgebase	25	<a href="https://darkkinome.org/">https://darkkinome.org/</a>
<b>Standard protein and gene names</b>		
UniProt	26	<a href="https://www.uniprot.org/">https://www.uniprot.org/</a>
HGNC	36	<a href="https://www.genenames.org/">https://www.genenames.org/</a>
<b>Enrichment analysis</b>		
Enrichr	56	<a href="https://maayanlab.cloud/Enrichr/">https://maayanlab.cloud/Enrichr/</a>
GSEAPy	65	<a href="https://pypi.org/project/gseapy/">https://pypi.org/project/gseapy/</a>
InterPro (domains)	38	<a href="https://www.ebi.ac.uk/interpro/">https://www.ebi.ac.uk/interpro/</a>
KEGG (pathways)	28	<a href="https://www.genome.jp/kegg/pathway.html">https://www.genome.jp/kegg/pathway.html</a>
<b>Web development and visualization</b>		
tidyverse	67	<a href="https://cran.r-project.org/package=tidyverse">https://cran.r-project.org/package=tidyverse</a>
shiny	61	<a href="https://cran.r-project.org/package=shiny">https://cran.r-project.org/package=shiny</a>
flexdashboard	62	<a href="https://cran.r-project.org/package=flexdashboard">https://cran.r-project.org/package=flexdashboard</a>
visNetwork	63	<a href="https://cran.r-project.org/package=visNetwork">https://cran.r-project.org/package=visNetwork</a>
igraph	64	<a href="https://cran.r-project.org/package=igraph">https://cran.r-project.org/package=igraph</a>
<b>Data extraction analysis and visualization in Python</b>		
pandas	68	<a href="https://pypi.org/project/pandas/">https://pypi.org/project/pandas/</a>
BeautifulSoup		<a href="https://pypi.org/project/beautifulsoup4/">https://pypi.org/project/beautifulsoup4/</a>
matplotlib_venn		<a href="https://pypi.org/project/matplotlib_venn">https://pypi.org/project/matplotlib_venn</a>
seaborn	69	<a href="https://pypi.org/project/seaborn/">https://pypi.org/project/seaborn/</a>



## 343 **References**

- 344 1. Fischer, E.H. (1997). Cellular regulation by protein phosphorylation: a historical  
345 overview. *BioFactors* 6, 367–374. 10.1002/biof.5520060307.
- 346 2. Pawson, T., and Scott, J.D. (2005). Protein phosphorylation in signaling – 50 years  
347 and counting. *Trends Biochem. Sci.* 30, 286–290. 10.1016/j.tibs.2005.04.013.
- 348 3. Fleuren, E.D.G., Zhang, L., Wu, J., and Daly, R.J. (2016). The kinome “at large” in  
349 cancer. *Nat. Rev. Cancer* 16, 83–98. 10.1038/nrc.2015.18.
- 350 4. Alganem, K., Hamoud, A.-R., Creeden, J.F., Henkel, N.D., Imami, A.S., Joyce, A.W.,  
351 Ryan V, W.G., Rethman, J.B., Shukla, R., O’Donovan, S.M., et al. (2022). The active kinome:  
352 The modern view of how active protein kinase networks fit in biological research. *Curr.*  
353 *Opin. Pharmacol.* 62, 117–129. 10.1016/j.coph.2021.11.007.
- 354 5. Wu, P., Nielsen, T.E., and Clausen, M.H. (2015). FDA-approved small-molecule  
355 kinase inhibitors. *Trends Pharmacol. Sci.* 36, 422–439. 10.1016/j.tips.2015.04.005.
- 356 6. Berndt, N., Karim, R.M., and Schönbrunn, E. (2017). Advances of small molecule  
357 targeting of kinases. *Curr. Opin. Chem. Biol.* 39, 126–132. 10.1016/j.cbpa.2017.06.015.
- 358 7. Munoz, L. (2017). Non-kinase targets of protein kinase inhibitors. *Nat. Rev. Drug*  
359 *Discov.* 16, 424–440. 10.1038/nrd.2016.266.
- 360 8. Huttlin, E.L., Bruckner, R.J., Paulo, J.A., Cannon, J.R., Ting, L., Baltier, K., Colby, G.,  
361 Gebreab, F., Gygi, M.P., Parzen, H., et al. (2017). Architecture of the human interactome  
362 defines protein communities and disease networks. *Nature* 545, 505–509.  
363 10.1038/nature22366.
- 364 9. Buljan, M., Ciuffa, R., van Drogen, A., Vichalkovski, A., Mehnert, M., Rosenberger,  
365 G., Lee, S., Varjosalo, M., Pernas, L.E., Spegg, V., et al. (2020). Kinase Interaction Network  
366 Expands Functional and Disease Roles of Human Kinases. *Mol. Cell* 79, 504-520.e9.  
367 10.1016/j.molcel.2020.07.001.
- 368 10. Rahman, R., Ung, P.M.-U., and Schlessinger, A. (2019). KinaMetrix: a web resource  
369 to investigate kinase conformations and inhibitor space. *Nucleic Acids Res.* 47, D361–  
370 D366. 10.1093/nar/gky916.
- 371 11. Modi, V., and Dunbrack, R.L., Jr (2022). Kincore: a web resource for structural  
372 classification of protein kinases and their inhibitors. *Nucleic Acids Res.* 50, D654–D664.  
373 10.1093/nar/gkab920.
- 374 12. Kooistra, A.J., Kanev, G.K., van Linden, O.P.J., Leurs, R., de Esch, I.J.P., and  
375 de Graaf, C. (2016). KLIFS: a structural kinase-ligand interaction database. *Nucleic Acids*  
376 *Res.* 44, D365–D371. 10.1093/nar/gkv1082.
- 377 13. Johnson, J.L., Yaron, T.M., Huntsman, E.M., Kerelsky, A., Song, J., Regev, A., Lin,  
378 T.-Y., Liberatore, K., Cizin, D.M., Cohen, B.M., et al. (2023). An atlas of substrate

- 379 specificities for the human serine/threonine kinome. *Nature* *613*, 759–766.  
380 10.1038/s41586-022-05575-3.
- 381 14. Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C.,  
382 Dimitriadou, S., Liu, D.L., Kantheti, H.S., Saghafeinia, S., et al. (2018). Oncogenic Signaling  
383 Pathways in The Cancer Genome Atlas. *Cell* *173*, 321–337.e10.  
384 10.1016/j.cell.2018.03.035.
- 385 15. Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor-tyrosine  
386 kinases. *Cell* *141*, 1117–1134. 10.1016/j.cell.2010.06.011.
- 387 16. Pearce, L.R., Komander, D., and Alessi, D.R. (2010). The nuts and bolts of AGC  
388 protein kinases. *Nat. Rev. Mol. Cell Biol.* *11*, 9–22. 10.1038/nrm2822.
- 389 17. Varjosalo, M., Keskitalo, S., Van Droogen, A., Nurkkala, H., Vichalkovski, A.,  
390 Aebbersold, R., and Gstaiger, M. (2013). The Protein Interaction Landscape of the Human  
391 CMGC Kinase Group. *Cell Rep.* *3*, 1306–1320. 10.1016/j.celrep.2013.03.027.
- 392 18. Ullah, R., Yin, Q., Snell, A.H., and Wan, L. (2022). RAF-MEK-ERK pathway in cancer  
393 evolution and treatment. *Semin. Cancer Biol.* *85*, 123–154.  
394 10.1016/j.semcancer.2021.05.010.
- 395 19. Vasta, J.D., Corona, C.R., Wilkinson, J., Zimprich, C.A., Hartnett, J.R., Ingold, M.R.,  
396 Zimmerman, K., Machleidt, T., Kirkland, T.A., Huwiler, K.G., et al. (2018). Quantitative,  
397 Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on  
398 Target Engagement. *Cell Chem. Biol.* *25*, 206–214.e11. 10.1016/j.chembiol.2017.10.010.
- 399 20. Hornbeck, P.V., Kornhauser, J.M., Latham, V., Murray, B., Nandhikonda, V., Nord, A.,  
400 Skrzypek, E., Wheeler, T., Zhang, B., and Gnad, F. (2019). 15 years of PhosphoSitePlus®:  
401 integrating post-translationally modified sites, disease variants and isoforms. *Nucleic  
402 Acids Res.* *47*, D433–D441. 10.1093/nar/gky1159.
- 403 21. Huang, H., Arighi, C.N., Ross, K.E., Ren, J., Li, G., Chen, S.-C., Wang, Q., Cowart,  
404 J., Vijay-Shanker, K., and Wu, C.H. (2018). iPTMnet: an integrated resource for protein  
405 post-translational modification network discovery. *Nucleic Acids Res.* *46*, D542–D550.  
406 10.1093/nar/gkx1104.
- 407 22. Lin, S., Wang, C., Zhou, J., Shi, Y., Ruan, C., Tu, Y., Yao, L., Peng, D., and Xue, Y.  
408 (2021). EPSD: a well-annotated data resource of protein phosphorylation sites in  
409 eukaryotes. *Brief. Bioinform.* *22*, 298–307. 10.1093/bib/bbz169.
- 410 23. Eid, S., Turk, S., Volkamer, A., Rippmann, F., and Fulle, S. (2017). KinMap: a web-  
411 based tool for interactive navigation through human kinome data. *BMC Bioinformatics* *18*,  
412 1–6. 10.1186/s12859-016-1433-7.
- 413 24. Metz, K.S., Deoudes, E.M., Berginski, M.E., Jimenez-Ruiz, I., Aksoy, B.A.,  
414 Hammerbacher, J., Gomez, S.M., and Phanstiel, D.H. (2018). Coral: Clear and

- 415 Customizable Visualization of Human Kinome Data. *Cell Syst.* 7, 347-350.e1.  
416 10.1016/j.cels.2018.07.001.
- 417 25. Berginski, M.E., Moret, N., Liu, C., Goldfarb, D., Sorger, P.K., and Gomez, S.M.  
418 (2021). The Dark Kinase Knowledgebase: an online compendium of knowledge and  
419 experimental results of understudied kinases. *Nucleic Acids Res.* 49, D529–D535.  
420 10.1093/nar/gkaa853.
- 421 26. Breuza, L., Poux, S., Estreicher, A., Famiglietti, M.L., Magrane, M., Tognolli, M.,  
422 Bridge, A., Baratin, D., Redaschi, N., and The UniProt Consortium (2016). The UniProtKB  
423 guide to the human proteome. *Database 2016*, bav120. 10.1093/database/bav120.
- 424 27. Oughtred, R., Rust, J., Chang, C., Breitkreutz, B.-J., Stark, C., Willems, A., Boucher,  
425 L., Leung, G., Kolas, N., Zhang, F., et al. (2021). The BioGRID database: A comprehensive  
426 biomedical resource of curated protein, genetic, and chemical interactions. *Protein Sci.*  
427 30, 187–200. 10.1002/pro.3978.
- 428 28. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., and Tanabe, M. (2016). KEGG  
429 as a reference resource for gene and protein annotation. *Nucleic Acids Res.* 44, D457–  
430 D462. 10.1093/nar/gkv1070.
- 431 29. Jassal, B., Matthews, L., Viteri, G., Gong, C., Lorente, P., Fabregat, A., Sidiropoulos,  
432 K., Cook, J., Gillespie, M., Haw, R., et al. (2020). The reactome pathway knowledgebase.  
433 *Nucleic Acids Res.* 48, D498–D503. 10.1093/nar/gkz1031.
- 434 30. Rodchenkov, I., Babur, O., Luna, A., Aksoy, B.A., Wong, J.V., Fong, D., Franz, M.,  
435 Siper, M.C., Cheung, M., Wrana, M., et al. (2020). Pathway Commons 2019 Update:  
436 integration, analysis and exploration of pathway data. *Nucleic Acids Res.* 48, D489–D497.  
437 10.1093/nar/gkz946.
- 438 31. Savage, S.R., and Zhang, B. (2020). Using phosphoproteomics data to understand  
439 cellular signaling: a comprehensive guide to bioinformatics resources. *Clin. Proteomics*  
440 17, 27. 10.1186/s12014-020-09290-x.
- 441 32. Dinkel, H., Chica, C., Via, A., Gould, C.M., Jensen, L.J., Gibson, T.J., and Diella, F.  
442 (2011). Phospho.ELM: a database of phosphorylation sites—update 2011. *Nucleic Acids*  
443 *Res.* 39, D261–D267. 10.1093/nar/gkq1104.
- 444 33. Suo, S.-B., Qiu, J.-D., Shi, S.-P., Chen, X., and Liang, R.-P. (2014). PSEA: Kinase-  
445 specific prediction and analysis of human phosphorylation substrates. *Sci. Rep.* 4, 4524.  
446 10.1038/srep04524.
- 447 34. Jung, I., Matsuyama, A., Yoshida, M., and Kim, D. (2010). PostMod: sequence based  
448 prediction of kinase-specific phosphorylation sites with indirect relationship. *BMC*  
449 *Bioinformatics* 11, 1–10. 10.1186/1471-2105-11-S1-S10.

- 450 35. Lee, T.-Y., Bo-Kai Hsu, J., Chang, W.-C., and Huang, H.-D. (2011). RegPhos: a  
451 system to explore the protein kinase–substrate phosphorylation network in humans.  
452 *Nucleic Acids Res.* *39*, D777–D787. 10.1093/nar/gkq970.
- 453 36. Seal, R.L., Braschi, B., Gray, K., Jones, T.E.M., Tweedie, S., Haim-Vilmovsky, L., and  
454 Bruford, E.A. (2023). Genenames.org: the HGNC resources in 2023. *Nucleic Acids Res.*  
455 *51*, D1003–D1009. 10.1093/nar/gkac888.
- 456 37. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The  
457 Protein Kinase Complement of the Human Genome. *Science* *298*, 1912–1934.  
458 10.1126/science.1075762.
- 459 38. Paysan-Lafosse, T., Blum, M., Chuguransky, S., Grego, T., Pinto, B.L., Salazar, G.A.,  
460 Bileschi, M.L., Bork, P., Bridge, A., Colwell, L., et al. (2023). InterPro in 2022. *Nucleic Acids*  
461 *Res.* *51*, D418–D427. 10.1093/nar/gkac993.
- 462 39. Himsolt, M. (1997). GML: Graph modelling language. Univ. Passau.
- 463 40. Brandes, U., Eiglsperger, M., Lerner, J., and Pich, C. (2010). Graph markup  
464 language (GraphML). Univ. Konstanz.
- 465 41. Gansner, E., Koutsofios, E., and North, S. (2006). Drawing graphs with dot (AT&T  
466 Research).
- 467 42. Morrison, D.K. (2012). MAP Kinase Pathways. *Cold Spring Harb. Perspect. Biol.* *4*,  
468 a011254. 10.1101/cshperspect.a011254.
- 469 43. Polzien, L., Baljuls, A., Rennefahrt, U.E.E., Fischer, A., Schmitz, W., Zahedi, R.P.,  
470 Sickmann, A., Metz, R., Albert, S., Benz, R., et al. (2009). Identification of Novel in Vivo  
471 Phosphorylation Sites of the Human Proapoptotic Protein BAD: PORE-FORMING  
472 ACTIVITY OF BAD IS REGULATED BY PHOSPHORYLATION \*. *J. Biol. Chem.* *284*,  
473 28004–28020. 10.1074/jbc.M109.010702.
- 474 44. Sanges, C., Scheuermann, C., Zahedi, R.P., Sickmann, A., Lamberti, A., Migliaccio,  
475 N., Baljuls, A., Marra, M., Zappavigna, S., Reinders, J., et al. (2012). Raf kinases mediate  
476 the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability  
477 in eukaryotic cells. *Cell Death Dis.* *3*, e276–e276. 10.1038/cddis.2012.16.
- 478 45. Li, X., Augustine, A., Sun, D., Li, L., and Fliegel, L. (2016). Activation of the Na<sup>+</sup>/H<sup>+</sup>  
479 exchanger in isolated cardiomyocytes through  $\beta$ -Raf dependent pathways. Role of Thr653  
480 of the cytosolic tail. *J. Mol. Cell. Cardiol.* *99*, 65–75. 10.1016/j.yjmcc.2016.08.014.
- 481 46. Guan, K.-L., Figueroa, C., Brtva, T.R., Zhu, T., Taylor, J., Barber, T.D., and Vojtek,  
482 A.B. (2000). Negative Regulation of the Serine/Threonine Kinase B-Raf by Akt \*. *J. Biol.*  
483 *Chem.* *275*, 27354–27359. 10.1016/S0021-9258(19)61518-8.
- 484 47. Cheung, M., Sharma, A., Madhunapantula, S.V., and Robertson, G.P. (2008). Akt3  
485 and mutant V600E B-Raf cooperate to promote early melanoma development. *Cancer*  
486 *Res.* *68*, 3429–3439. 10.1158/0008-5472.CAN-07-5867.

- 487 48. Duan, L., and Cobb, M.H. (2010). Calcineurin increases glucose activation of  
488 ERK1/2 by reversing negative feedback. *Proc. Natl. Acad. Sci.* *107*, 22314–22319.  
489 10.1073/pnas.1016630108.
- 490 49. Wallert, M.A., Hammes, D., Nguyen, T., Kiefer, L., Berthelsen, N., Kern, A.,  
491 Anderson-Tiege, K., Shabb, J.B., Muhonen, W.W., Grove, B.D., et al. (2015). RhoA Kinase  
492 (Rock) and p90 Ribosomal S6 Kinase (p90Rsk) phosphorylation of the sodium hydrogen  
493 exchanger (NHE1) is required for lysophosphatidic acid-induced transport, cytoskeletal  
494 organization and migration. *Cell. Signal.* *27*, 498–509. 10.1016/j.cellsig.2015.01.002.
- 495 50. Snabaitis, A.K., Cuello, F., and Avkiran, M. (2008). Protein Kinase B/Akt  
496 Phosphorylates and Inhibits the Cardiac Na<sup>+</sup>/H<sup>+</sup> Exchanger NHE1. *Circ. Res.* *103*, 881–  
497 890. 10.1161/CIRCRESAHA.108.175877.
- 498 51. Hendus-Altenburger, R., Lambrughi, M., Terkelsen, T., Pedersen, S.F., Papaleo, E.,  
499 Lindorff-Larsen, K., and Kragelund, B.B. (2017). A phosphorylation-motif for tuneable helix  
500 stabilisation in intrinsically disordered proteins – Lessons from the sodium proton  
501 exchanger 1 (NHE1). *Cell. Signal.* *37*, 40–51. 10.1016/j.cellsig.2017.05.015.
- 502 52. Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T.,  
503 Kaimachnikov, N.P., Timmer, J., Hoek, J.B., and Kholodenko, B.N. (2009). Systems-level  
504 interactions between insulin–EGF networks amplify mitogenic signaling. *Mol. Syst. Biol.* *5*,  
505 256. 10.1038/msb.2009.19.
- 506 53. Barnum, K.J., and O’Connell, M.J. (2014). Cell Cycle Regulation by Checkpoints.  
507 In *Cell Cycle Control: Mechanisms and Protocols Methods in Molecular Biology.*, E.  
508 Noguchi and M. C. Gadaleta, eds. (Springer), pp. 29–40. 10.1007/978-1-4939-0888-2\_2.
- 509 54. Fujimoto, K., Takahashi, S.Y., and Katoh, S. (2002). Mutational analysis of sites in  
510 sepiapterin reductase phosphorylated by Ca<sup>2+</sup>/calmodulin-dependent protein kinase II.  
511 *Biochim. Biophys. Acta BBA - Protein Struct. Mol. Enzymol.* *1594*, 191–198.  
512 10.1016/S0167-4838(01)00300-4.
- 513 55. Wu, Y., Chen, P., Sun, L., Yuan, S., Cheng, Z., Lu, L., Du, H., and Zhan, M. (2020).  
514 Sepiapterin reductase: Characteristics and role in diseases. *J. Cell. Mol. Med.* *24*, 9495–  
515 9506. 10.1111/jcmm.15608.
- 516 56. Xie, Z., Bailey, A., Kuleshov, M.V., Clarke, D.J.B., Evangelista, J.E., Jenkins, S.L.,  
517 Lachmann, A., Wojciechowicz, M.L., Kropiwnicki, E., Jagodnik, K.M., et al. (2021). Gene  
518 Set Knowledge Discovery with Enrichr. *Curr. Protoc.* *1*, e90. 10.1002/cpz1.90.
- 519 57. Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z.,  
520 Koplev, S., Jenkins, S.L., Jagodnik, K.M., Lachmann, A., et al. (2016). Enrichr: a  
521 comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.*  
522 *44*, W90–W97. 10.1093/nar/gkw377.
- 523 58. Kurochkina, N., and Guha, U. (2013). SH3 domains: modules of protein–protein  
524 interactions. *Biophys. Rev.* *5*, 29–39. 10.1007/s12551-012-0081-z.




- 525 59. Bahl, S., and Seto, E. (2021). Regulation of histone deacetylase activities and  
526 functions by phosphorylation and its physiological relevance. *Cell. Mol. Life Sci.* 78, 427–  
527 445. [10.1007/s00018-020-03599-4](https://doi.org/10.1007/s00018-020-03599-4).
- 528 60. Kee, J., Thudium, S., Renner, D.M., Glastad, K., Palozola, K., Zhang, Z., Li, Y., Lan,  
529 Y., Cesare, J., Poleshko, A., et al. (2022). SARS-CoV-2 disrupts host epigenetic regulation  
530 via histone mimicry. *Nature* 610, 381–388. [10.1038/s41586-022-05282-z](https://doi.org/10.1038/s41586-022-05282-z).
- 531 61. Chang, W., Cheng, J., Allaire, J., Sievert, C., Schloerke, B., Xie, Y., Allen, J.,  
532 McPherson, J., Dipert, A., and Borges, B. (2023). shiny: Web application framework for R.
- 533 62. Aden-Buie, G., Sievert, C., Iannone, R., Allaire, J., and Borges, B. (2023).  
534 flexdashboard: R markdown format for flexible dashboards.
- 535 63. Almende, B.V., and Benoit, T. (2022). visNetwork: Network Visualization using  
536 “vis.js” Library. Version 2.1.2.
- 537 64. Csardi, G., and Nepusz, T. (2006). The igraph software package for complex  
538 network research. *InterJournal Complex Systems*, 1695.
- 539 65. Fang, Z., Liu, X., and Peltz, G. (2023). GSEAPy: a comprehensive package for  
540 performing gene set enrichment analysis in Python. *Bioinformatics* 39, btac757.  
541 [10.1093/bioinformatics/btac757](https://doi.org/10.1093/bioinformatics/btac757).
- 542 66. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A  
543 Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* 57,  
544 289–300. [10.1111/j.2517-6161.1995.tb02031.x](https://doi.org/10.1111/j.2517-6161.1995.tb02031.x).
- 545 67. Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L.D., François, R.,  
546 Grolemond, G., Hayes, A., Henry, L., Hester, J., et al. (2019). Welcome to the Tidyverse. *J.*  
547 *Open Source Softw.* 4, 1686. [10/ggddkj](https://doi.org/10/ggddkj).
- 548 68. Wes McKinney (2010). Data Structures for Statistical Computing in Python. In  
549 *Proceedings of the 9th Python in Science Conference*, S. van der Walt and Jarrod Millman,  
550 eds., pp. 56–61. [10.25080/Majora-92bf1922-00a](https://doi.org/10.25080/Majora-92bf1922-00a).
- 551 69. Waskom, M.L. (2021). seaborn: statistical data visualization. *J. Open Source Softw.*  
552 6, 3021. [10.21105/joss.03021](https://doi.org/10.21105/joss.03021).
- 553




554 **Supplementary Figures**

555 **Figure S1: Degree distributions in the KinAce dataset. (a) Substrates per kinase. (b) Kinases**  
556 **per substrate.** Both distributions have heavy right tails, suggesting that a small number of kinases  
557 and substrates dominate the set of interactions.




558

559 **Figure S2: Visualization of the MAPK signaling pathway.** The network shown when MAPK  
560 signaling is selected in the Pathways tab and grid layout is applied.




562 **Figure S3: Enrichment analyses of kinase substrates in the KinAce dataset. (a) KEGG**  
563 **pathways.** This analysis highlighted 201 enriched pathways in six KEGG categories,  
564 shown here. The full set of enriched pathways and their p-values are provided in  
565 **Appendix 1. (b) InterPro domains.** This analysis highlighted 145 enriched domain terms  
566 in five functional categories, shown here. The full set of enriched domain terms and their  
567 p-values are provided in **Appendix 2.**

**a**




**b**



568

569 **Figure S4: Visualization of proteins with SH3 domain.** The network shown when SH3 domain  
570 is selected in the Domains tab and grid layout is applied. Note the prevalence of Src-type  
571 kinases, such as SRC, FYN, FGR, LCK and LYN.



572



573 **Appendix 1: Results of pathway enrichment analysis of kinase**  
 574 **substrates in the KinAce dataset.**

<b>KEGG Term</b>	<b>KEGG Category</b>	<b>Adjusted p-value</b>
Pathways in cancer	Human Diseases	1.53E-70
MAPK signaling pathway	Environmental Information Processing	6.87E-61
Hepatitis B	Human Diseases	1.39E-54
Neurotrophin signaling pathway	Organismal Systems	3.73E-53
MicroRNAs in cancer	Human Diseases	5.47E-53
Human T-cell leukemia virus 1 infection	Human Diseases	1.97E-49
Shigellosis	Human Diseases	3.75E-49
Yersinia infection	Human Diseases	3.68E-48
Viral carcinogenesis	Human Diseases	1.22E-47
Proteoglycans in cancer	Human Diseases	6.21E-44
Cell cycle	Cellular Processes	1.69E-43
T cell receptor signaling pathway	Organismal Systems	2.72E-43
Lipid and atherosclerosis	Human Diseases	7.22E-43
Cellular senescence	Cellular Processes	2.87E-42
ErbB signaling pathway	Environmental Information Processing	1.63E-41
Insulin signaling pathway	Organismal Systems	2.34E-41
Pathways of neurodegeneration	Human Diseases	2.27E-39
FoxO signaling pathway	Environmental Information Processing	2.53E-39
Epstein-Barr virus infection	Human Diseases	1.30E-38
Chronic myeloid leukemia	Human Diseases	1.72E-38
Focal adhesion	Cellular Processes	4.44E-38
PI3K-Akt signaling pathway	Environmental Information Processing	5.12E-38
Human immunodeficiency virus 1 infection	Human Diseases	1.11E-37
Kaposi sarcoma-associated herpesvirus infection	Human Diseases	3.11E-37
Salmonella infection	Human Diseases	3.68E-37
PD-L1 expression and PD-1 checkpoint pathway in cancer	Human Diseases	3.98E-36
Osteoclast differentiation	Organismal Systems	4.24E-36
Autophagy	Cellular Processes	7.90E-36
Regulation of actin cytoskeleton	Cellular Processes	1.89E-35
Measles	Human Diseases	3.70E-35
Hepatitis C	Human Diseases	5.04E-34
Apoptosis	Cellular Processes	7.65E-34
Ras signaling pathway	Environmental Information Processing	9.02E-34

Prostate cancer	Human Diseases	1.63E-33
Pancreatic cancer	Human Diseases	2.84E-33
Human cytomegalovirus infection	Human Diseases	6.36E-32
Human papillomavirus infection	Human Diseases	4.22E-31
Alzheimer disease	Human Diseases	8.93E-31
Colorectal cancer	Human Diseases	1.27E-30
cAMP signaling pathway	Environmental Information Processing	3.14E-30
Insulin resistance	Human Diseases	3.60E-30
Rap1 signaling pathway	Environmental Information Processing	4.43E-30
Fc gamma R-mediated phagocytosis	Organismal Systems	4.60E-30
Pathogenic Escherichia coli infection	Human Diseases	1.05E-29
Growth hormone synthesis, secretion and action	Organismal Systems	2.75E-29
Longevity regulating pathway	Organismal Systems	2.12E-28
Acute myeloid leukemia	Human Diseases	3.31E-28
C-type lectin receptor signaling pathway	Organismal Systems	1.07E-27
Renal cell carcinoma	Human Diseases	1.09E-27
AGE-RAGE signaling pathway in diabetic complications	Human Diseases	3.65E-27
AMPK signaling pathway	Environmental Information Processing	3.69E-27
HIF-1 signaling pathway	Environmental Information Processing	5.58E-27
Non-small cell lung cancer	Human Diseases	6.44E-27
Chemokine signaling pathway	Organismal Systems	1.02E-26
Sphingolipid signaling pathway	Environmental Information Processing	1.36E-26
Tight junction	Cellular Processes	4.33E-26
Thyroid hormone signaling pathway	Organismal Systems	5.27E-26
Transcriptional misregulation in cancer	Human Diseases	1.02E-25
Endocytosis	Cellular Processes	1.09E-25
Prolactin signaling pathway	Organismal Systems	1.32E-25
Central carbon metabolism in cancer	Human Diseases	1.32E-25
Glioma	Human Diseases	1.32E-25
mTOR signaling pathway	Environmental Information Processing	1.42E-25
Adherens junction	Cellular Processes	3.69E-25
Leukocyte transendothelial migration	Organismal Systems	6.92E-25
Endometrial cancer	Human Diseases	1.93E-24
TNF signaling pathway	Environmental Information Processing	2.63E-24
Hepatocellular carcinoma	Human Diseases	3.89E-24
Axon guidance	Organismal Systems	4.47E-24
Fc epsilon RI signaling pathway	Organismal Systems	4.55E-24



Fluid shear stress and atherosclerosis	Human Diseases	5.30E-24
NOD-like receptor signaling pathway	Organismal Systems	1.38E-23
Oxytocin signaling pathway	Organismal Systems	1.50E-23
Breast cancer	Human Diseases	2.06E-23
Mitophagy	Cellular Processes	3.38E-23
Neutrophil extracellular trap formation	Organismal Systems	5.23E-23
Platelet activation	Organismal Systems	5.32E-23
cGMP-PKG signaling pathway	Environmental Information Processing	6.04E-23
B cell receptor signaling pathway	Organismal Systems	1.21E-22
Th17 cell differentiation	Organismal Systems	2.52E-22
Progesterone-mediated oocyte maturation	Organismal Systems	9.80E-22
Gastric cancer	Human Diseases	1.03E-21
Apelin signaling pathway	Environmental Information Processing	2.06E-21
Chemical carcinogenesis	Human Diseases	4.04E-21
Toxoplasmosis	Human Diseases	5.61E-21
Bacterial invasion of epithelial cells	Human Diseases	8.79E-21
Necroptosis	Cellular Processes	9.11E-21
Toll-like receptor signaling pathway	Organismal Systems	1.25E-20
Phospholipase D signaling pathway	Environmental Information Processing	5.50E-20
Spinocerebellar ataxia	Human Diseases	6.71E-20
GnRH signaling pathway	Organismal Systems	1.00E-19
Hippo signaling pathway	Environmental Information Processing	1.33E-19
NF-kappa B signaling pathway	Environmental Information Processing	1.63E-19
Long-term potentiation	Organismal Systems	1.85E-19
Signaling pathways regulating pluripotency of stem cells	Cellular Processes	2.06E-19
Amyotrophic lateral sclerosis	Human Diseases	2.67E-19
Influenza A	Human Diseases	2.74E-19
Choline metabolism in cancer	Human Diseases	3.29E-19
Small cell lung cancer	Human Diseases	6.81E-19
VEGF signaling pathway	Environmental Information Processing	7.79E-19
Parathyroid hormone synthesis, secretion and action	Organismal Systems	8.97E-19
Diabetic cardiomyopathy	Human Diseases	1.40E-18
Oocyte meiosis	Cellular Processes	1.42E-18
p53 signaling pathway	Cellular Processes	2.22E-18
Cushing syndrome	Human Diseases	2.79E-18
Alcoholism	Human Diseases	1.34E-17
Bladder cancer	Human Diseases	1.53E-17

Chagas disease	Human Diseases	3.69E-17
Non-alcoholic fatty liver disease	Human Diseases	4.86E-17
Estrogen signaling pathway	Organismal Systems	5.64E-17
Adipocytokine signaling pathway	Organismal Systems	6.68E-17
IL-17 signaling pathway	Organismal Systems	9.29E-17
Tuberculosis	Human Diseases	9.95E-17
Calcium signaling pathway	Environmental Information Processing	1.29E-16
Relaxin signaling pathway	Organismal Systems	1.74E-16
Melanoma	Human Diseases	5.32E-16
Th1 and Th2 cell differentiation	Organismal Systems	1.10E-15
Coronavirus disease	Human Diseases	1.55E-15
Adrenergic signaling in cardiomyocytes	Organismal Systems	1.70E-15
Huntington disease	Human Diseases	9.58E-15
Parkinson disease	Human Diseases	1.99E-14
Type II diabetes mellitus	Human Diseases	3.18E-14
Prion disease	Human Diseases	4.12E-14
Leishmaniasis	Human Diseases	4.34E-14
Thyroid cancer	Human Diseases	1.21E-13
RIG-I-like receptor signaling pathway	Organismal Systems	1.88E-13
Glucagon signaling pathway	Organismal Systems	1.93E-13
Pertussis	Human Diseases	2.64E-13
Inflammatory mediator regulation of TRP channels	Organismal Systems	3.86E-13
GnRH secretion	Organismal Systems	3.93E-13
Dopaminergic synapse	Organismal Systems	4.34E-13
Wnt signaling pathway	Environmental Information Processing	4.54E-13
JAK-STAT signaling pathway	Environmental Information Processing	2.21E-12
Gap junction	Cellular Processes	3.70E-12
Ubiquitin mediated proteolysis	Genetic Information Processing	3.86E-12
Long-term depression	Organismal Systems	5.55E-12
Cholinergic synapse	Organismal Systems	1.42E-11
Natural killer cell mediated cytotoxicity	Organismal Systems	1.81E-11
Amphetamine addiction	Human Diseases	3.98E-11
Aldosterone synthesis and secretion	Organismal Systems	2.44E-10
Homologous recombination	Genetic Information Processing	2.67E-09
Non-homologous end-joining	Genetic Information Processing	2.95E-09
Vascular smooth muscle contraction	Organismal Systems	6.88E-09
Cocaine addiction	Human Diseases	7.13E-09

Epithelial cell signaling in Helicobacter pylori infection	Human Diseases	8.19E-09
Circadian entrainment	Organismal Systems	1.34E-07
RNA transport	Genetic Information Processing	1.44E-07
Aldosterone-regulated sodium reabsorption	Organismal Systems	2.66E-07
Melanogenesis	Organismal Systems	4.29E-07
Regulation of lipolysis in adipocytes	Organismal Systems	6.28E-07
Fanconi anemia pathway	Genetic Information Processing	1.24E-06
Legionellosis	Human Diseases	1.38E-06
Serotonergic synapse	Organismal Systems	2.47E-06
Primary immunodeficiency	Human Diseases	2.63E-06
Notch signaling pathway	Environmental Information Processing	2.88E-06
Circadian rhythm	Organismal Systems	7.54E-06
Thermogenesis	Organismal Systems	1.19E-05
Endocrine and other factor-regulated calcium reabsorption	Organismal Systems	2.07E-05
Protein processing in endoplasmic reticulum	Genetic Information Processing	2.19E-05
Phosphatidylinositol signaling system	Environmental Information Processing	3.55E-05
Hypertrophic cardiomyopathy	Human Diseases	5.45E-05
Insulin secretion	Organismal Systems	5.98E-05
Arrhythmogenic right ventricular cardiomyopathy	Human Diseases	1.63E-04
Cell adhesion molecules	Environmental Information Processing	1.84E-04
Base excision repair	Genetic Information Processing	2.45E-04
Gastric acid secretion	Organismal Systems	3.56E-04
Dilated cardiomyopathy	Human Diseases	4.06E-04
Hedgehog signaling pathway	Environmental Information Processing	4.39E-04
Inositol phosphate metabolism	Metabolism	4.89E-04
Renin secretion	Organismal Systems	5.43E-04
Retrograde endocannabinoid signaling	Organismal Systems	5.96E-04
Cortisol synthesis and secretion	Organismal Systems	5.96E-04
TGF-beta signaling pathway	Environmental Information Processing	6.58E-04
Vasopressin-regulated water reabsorption	Organismal Systems	6.68E-04
Glutamatergic synapse	Organismal Systems	7.52E-04
Glycolysis / Gluconeogenesis	Metabolism	9.21E-04
Ferroptosis	Cellular Processes	9.21E-04
Morphine addiction	Human Diseases	1.07E-03

Viral myocarditis	Human Diseases	1.13E-03
Salivary secretion	Organismal Systems	1.51E-03
Spliceosome	Genetic Information Processing	1.59E-03
Cytosolic DNA-sensing pathway	Organismal Systems	2.18E-03
Phagosome	Cellular Processes	2.23E-03
DNA replication	Genetic Information Processing	2.36E-03
Amoebiasis	Human Diseases	2.47E-03
Basal cell carcinoma	Human Diseases	2.64E-03
Purine metabolism	Metabolism	2.76E-03
mRNA surveillance pathway	Genetic Information Processing	3.30E-03
Systemic lupus erythematosus	Human Diseases	3.57E-03
Inflammatory bowel disease	Human Diseases	3.86E-03
Carbohydrate digestion and absorption	Organismal Systems	4.17E-03
Pyruvate metabolism	Metabolism	4.17E-03
Maturity onset diabetes of the young	Human Diseases	4.63E-03
Mismatch repair	Genetic Information Processing	6.48E-03
Nucleotide excision repair	Genetic Information Processing	9.07E-03
Bile secretion	Organismal Systems	9.17E-03
Pancreatic secretion	Organismal Systems	1.15E-02
Pentose phosphate pathway	Metabolism	1.44E-02
Citrate cycle (TCA cycle)	Metabolism	1.44E-02
Thyroid hormone synthesis	Organismal Systems	1.95E-02
Hematopoietic cell lineage	Organismal Systems	4.65E-02
Folate biosynthesis	Metabolism	4.76E-02

576 **Appendix 2: Results of domain enrichment analysis of kinase**  
 577 **substrates in the KinAce dataset.**

<b>InterPro Term</b>	<b>Category</b>	<b>Adjusted p-value</b>
Protein kinase domain	Catalytic	2.53E-130
Serine-threonine/tyrosine-protein kinase, catalytic domain	Catalytic	3.14E-38
Tyrosine-protein kinase, catalytic domain	Catalytic	1.08E-36
SH2 domain	Cytoplasmic	1.96E-30
AGC-kinase, C-terminal	Catalytic	4.83E-22
Protein kinase, C-terminal	Catalytic	3.32E-21
SH3 domain	Cytoplasmic	2.88E-20
Pleckstrin homology domain	Cytoplasmic	5.30E-17
Nuclear hormone receptor, ligand-binding domain	Nuclear	5.77E-12
Zinc finger, nuclear hormone receptor-type	Nuclear	9.81E-12
Diacylglycerol/phorbol-ester binding	Cytoplasmic	7.69E-11
Protein kinase C-like, phorbol ester/diacylglycerol-binding domain	Cytoplasmic	4.55E-10
Calponin homology domain	Structural	1.13E-08
BRCT domain	Cytoplasmic	3.33E-08
Basic-leucine zipper domain	Nuclear	7.17E-08
Ion transport domain	Transport	3.31E-07
Ubiquitin-associated domain	Cytoplasmic	1.23E-06
Ets domain	Nuclear	1.53E-06
PB1 domain	Cytoplasmic	7.65E-06
Rel homology dimerisation domain	Nuclear	1.15E-05
Rel homology domain (RHD), DNA-binding domain	Nuclear	1.15E-05
RNA recognition motif domain	Nuclear	1.46E-05
Zinc finger, PHD-type	Nuclear	1.91E-05
Myc-type, basic helix-loop-helix (bHLH) domain	Nuclear	3.04E-05
Histone deacetylase domain	Nuclear	4.49E-05
STAT transcription factor, protein interaction	Nuclear	4.49E-05
STAT transcription factor, DNA-binding	Nuclear	4.49E-05
STAT transcription factor, all-alpha domain	Nuclear	4.49E-05
Zinc finger, PHD-finger	Nuclear	5.60E-05
Cyclin-like	Cytoplasmic	1.11E-04
CRIB domain	Cytoplasmic	2.29E-04
p21 activated kinase binding domain	Cytoplasmic	2.63E-04
SLC12A transporter, C-terminal	Transport	2.65E-04
Dbl homology (DH) domain	Catalytic	3.11E-04
Tyrosine specific protein phosphatases domain	Catalytic	3.52E-04
RGS domain	Cytoplasmic	4.59E-04
WW domain	Cytoplasmic	5.90E-04

SAP domain	Nuclear	6.52E-04
Peptidase C14, p20 domain	Catalytic	6.90E-04
IPT domain	Nuclear	6.90E-04
PAS fold	Nuclear	6.99E-04
Protein-tyrosine phosphatase, catalytic	Catalytic	6.99E-04
Forkhead-associated (FHA) domain	Catalytic	7.72E-04
Amino acid permease/ SLC12A domain	Transport	7.77E-04
Furin-like cysteine-rich domain	Cytoplasmic	1.07E-03
14-3-3 domain	Cytoplasmic	1.07E-03
Receptor L-domain	Cytoplasmic	1.07E-03
Integrin beta subunit, tail	Structural	1.07E-03
Transcription factor, MADS-box	Nuclear	1.11E-03
NFkappaB IPT domain	Nuclear	1.11E-03
Kinase associated domain 1 (KA1)	Catalytic	1.11E-03
PAS domain	Cytoplasmic	1.28E-03
Actin-depolymerising factor homology domain	Structural	1.87E-03
Phosphatidylinositol 3-/4-kinase, catalytic domain	Catalytic	1.94E-03
Bromodomain	Nuclear	1.98E-03
PTB/PI domain	Cytoplasmic	1.98E-03
Peptidase C14A, caspase catalytic domain	Catalytic	2.08E-03
DEP domain	Cytoplasmic	2.51E-03
PTP type protein phosphatase	Catalytic	2.59E-03
Cold-shock protein, DNA-binding	Nuclear	2.76E-03
Cold shock domain	Nuclear	2.76E-03
MAD homology, MH1	Nuclear	2.76E-03
Integrin beta subunit, VWA domain	Structural	2.76E-03
SMAD domain, Dwarfing-type	Nuclear	2.76E-03
Integrin beta N-terminal	Structural	2.76E-03
Cyclin, N-terminal	Cytoplasmic	3.02E-03
PDZ domain	Cytoplasmic	3.20E-03
Cyclin, C-terminal domain	Cytoplasmic	3.20E-03
HD/PDEase domain	Catalytic	3.37E-03
Pointed domain	Nuclear	3.39E-03
Transient receptor ion channel domain	Transport	3.99E-03
MCM N-terminal domain	Nuclear	3.99E-03
3'5'-cyclic nucleotide phosphodiesterase, catalytic domain	Catalytic	3.99E-03
Calmodulin-regulated spectrin-associated protein, CH domain	Structural	3.99E-03
Integrin beta subunit, cytoplasmic domain	Structural	3.99E-03
Zinc finger, GATA-type	Nuclear	5.82E-03
Ras GTPase-activating domain	Cytoplasmic	5.82E-03
Phosphatidylinositol-4-phosphate 5-kinase, core	Cytoplasmic	5.95E-03
Myb domain	Nuclear	5.95E-03



MATH/TRAF domain	Catalytic	6.05E-03
Ran binding domain	Cytoplasmic	6.05E-03
Peptidase C14, caspase non-catalytic subunit p10	Catalytic	6.05E-03
Rho GTPase-activating protein domain	Cytoplasmic	8.45E-03
Potassium channel, inwardly rectifying, transmembrane domain	Transport	9.28E-03
CARD domain	Cytoplasmic	9.29E-03
Syndecan/Neurexin domain	Structural	1.01E-02
W2 domain	Nuclear	1.01E-02
DIX domain	Cytoplasmic	1.01E-02
Raf-like Ras-binding	Cytoplasmic	1.01E-02
Sirtuin family, catalytic core domain	Catalytic	1.01E-02
CAP Gly-rich domain	Structural	1.12E-02
Phosphoinositide 3-kinase, accessory (PIK) domain	Catalytic	1.12E-02
K Homology domain	Nuclear	1.15E-02
Rhodanese-like domain	Catalytic	1.15E-02
Helicase, C-terminal	Nuclear	1.18E-02
HECT domain	Catalytic	1.18E-02
Kinesin motor domain	Structural	1.26E-02
Ankyrin repeat-containing domain	Cytoplasmic	1.36E-02
Band 4.1 domain	Cytoplasmic	1.42E-02
K Homology domain, type 1	Nuclear	1.44E-02
Tubulin/FtsZ, 2-layer sandwich domain	Structural	1.45E-02
WH2 domain	Structural	1.45E-02
APBB1IP, PH domain	Cytoplasmic	1.47E-02
MYST, zinc finger domain	Nuclear	1.47E-02
PIK-related kinase, FAT	Catalytic	1.47E-02
Chromo/chromo shadow domain	Nuclear	1.47E-02
Zinc finger, RanBP2-type	Nuclear	1.47E-02
PWI domain	Nuclear	1.47E-02
Ephrin receptor, transmembrane domain	Catalytic	1.47E-02
Histone acetyltransferase domain, MYST-type	Catalytic	1.47E-02
Ephrin receptor ligand binding domain	Cytoplasmic	1.47E-02
Helicase superfamily 1/2, ATP-binding domain	Nuclear	1.47E-02
Integrin beta, epidermal growth factor-like domain 1	Structural	1.47E-02
Rho GTPase-binding/formin homology 3 (GBD/FH3) domain	Structural	1.71E-02
Bromo adjacent homology (BAH) domain	Nuclear	1.71E-02
Phosphatidylinositol 3-kinase, C2 domain	Catalytic	1.82E-02
MCM OB domain	Nuclear	1.82E-02
Ras-like guanine nucleotide exchange factor, N-terminal	Cytoplasmic	1.85E-02
Ubiquitin specific protease domain	Catalytic	2.01E-02
Sterile alpha motif domain	Nuclear	2.36E-02

Tubulin/FtsZ, GTPase domain	Structural	2.57E-02
MAD homology 1, Dwarfina-type	Nuclear	2.80E-02
IRS-type PTB domain	Cytoplasmic	2.80E-02
Small GTP-binding protein domain	Cytoplasmic	2.95E-02
Peptidase C19, ubiquitin carboxyl-terminal hydrolase	Catalytic	3.09E-02
Tetratricopeptide repeat-containing domain	Cytoplasmic	3.12E-02
Cold-shock (CSD) domain	Nuclear	3.12E-02
Rab-binding domain FIP-RBD	Catalytic	3.12E-02
FATC domain	Catalytic	3.12E-02
MCM domain	Nuclear	3.12E-02
PIK-related kinase	Catalytic	3.12E-02
CP2 transcription factor	Nuclear	3.12E-02
E2F transcription factor, CC-MB domain	Nuclear	3.12E-02
Histidine kinase/HSP90-like ATPase	Catalytic	3.12E-02
Serine/threonine-protein kinase OSR1/WNK, CCT domain	Catalytic	3.12E-02
Helicase/UvrB, N-terminal	Nuclear	3.12E-02
Growth factor receptor domain 4	Cytoplasmic	3.12E-02
Glutamine amidotransferase	Catalytic	3.12E-02
Formin, GTPase-binding domain	Structural	3.12E-02
Formin, FH3 domain	Structural	3.12E-02
Initiation factor eIF-4 gamma, MA3	Nuclear	3.12E-02
Dual specificity protein phosphatase domain	Catalytic	3.50E-02
Zinc finger, LIM-type	Nuclear	3.68E-02
PAS fold-3	Cytoplasmic	3.86E-02
Basic leucine zipper domain, Maf-type	Nuclear	3.86E-02
FERM domain	Cytoplasmic	4.52E-02
Dual specificity phosphatase, catalytic domain	Catalytic	4.82E-02